186 related articles for article (PubMed ID: 37097540)
1. Radiotherapy after radical prostatectomy for prostate cancer: clinical outcomes and factors influencing biochemical recurrence.
Fukuda I; Aoki M; Kimura T; Ikeda K
Ir J Med Sci; 2023 Dec; 192(6):2663-2671. PubMed ID: 37097540
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
[TBL] [Abstract][Full Text] [Related]
4. Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomy.
Kashihara T; Nakamura S; Wakita A; Okamoto H; Inaba K; Umezawa R; Shima S; Tsuchida K; Kobayashi K; Takahashi K; Murakami N; Ito Y; Igaki H; Fujimoto H; Uno T; Itami J
Cancer Med; 2018 May; 7(5):1723-1730. PubMed ID: 29573193
[TBL] [Abstract][Full Text] [Related]
5. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
Ravi P; Kwak L; Devlies W; Xie W; Chipidza F; Yang X; Bubley G; Kaplan I; Kibel AS; Nguyen P; Taplin ME
Prostate; 2024 Mar; 84(4):342-348. PubMed ID: 38041475
[TBL] [Abstract][Full Text] [Related]
7. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
8. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
[TBL] [Abstract][Full Text] [Related]
9. The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis.
Tao R; Dai J; Bai Y; Yang J; Sun G; Zhang X; Zhao J; Zeng H; Shen P
Radiat Oncol; 2019 Nov; 14(1):197. PubMed ID: 31706339
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.
Taylor N; Kelly JF; Kuban DA; Babaian RJ; Pisters LL; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):755-63. PubMed ID: 12788182
[TBL] [Abstract][Full Text] [Related]
11. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.
Ost P; Lumen N; Goessaert AS; Fonteyne V; De Troyer B; Jacobs F; De Meerleer G
Eur Urol; 2011 Oct; 60(4):842-9. PubMed ID: 21514039
[TBL] [Abstract][Full Text] [Related]
12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
13. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY
Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.
Hervás A; Gómez-Caamaño A; Casaña M; Gómez-Iturriaga A; Pastor J; Jove J; Mengual JL; Gónzalez-San Segundo C; Muñoz J
Clin Transl Oncol; 2018 Feb; 20(2):193-200. PubMed ID: 28667448
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.
Vogel MME; Kessel KA; Schiller K; Devecka M; Gschwend JE; Weichert W; Wilkens JJ; Combs SE
Radiat Oncol; 2019 Nov; 14(1):198. PubMed ID: 31711524
[TBL] [Abstract][Full Text] [Related]
16. Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.
Morgan TM; Hawken SR; Ghani KR; Miller DC; Feng FY; Linsell SM; Salisz JA; Gao Y; Montie JE; Cher ML
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):216-21. PubMed ID: 26951715
[TBL] [Abstract][Full Text] [Related]
17. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2529-2536. PubMed ID: 36905411
[TBL] [Abstract][Full Text] [Related]
18. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
Bottke D; Bartkowiak D; Siegmann A; Thamm R; Böhmer D; Budach V; Wiegel T
Prostate Cancer Prostatic Dis; 2019 May; 22(2):344-349. PubMed ID: 30487644
[TBL] [Abstract][Full Text] [Related]
19. Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml.
Umezawa R; Ariga H; Ogawa Y; Jingu K; Matsushita H; Takeda K; Fujimoto K; Sakayauchi T; Sugawara T; Kubozono M; Narazaki K; Shimizu E; Takai Y; Yamada S
Radiat Oncol; 2011 Nov; 6():150. PubMed ID: 22053922
[TBL] [Abstract][Full Text] [Related]
20. Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.
Casas F; Valduvieco I; Oses G; Izquierdo L; Archila I; Costa M; Cortes KS; Barreto T; Ferrer F
Clin Transl Oncol; 2019 Mar; 21(3):355-362. PubMed ID: 30128953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
